Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Lupin receives FDA approval for Ziprasidone Hydrochloride capsules

Lupin Pharmaceuticals has announced that on May 16, 2007 it received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Ziprasidone Hydrochloride Capsules 20mg, 40mg, 60mg and 80mg.

24 May 2007

Combination of medicines best for blood pressure control

Millions of Americans take medications for hypertension but do not achieve control of their blood pressure.

22 May 2007

Weill Cornell Medical College students help change global health policy

In a move to improve global public health, Weill Cornell Medical College students have helped place a lifesaving heart disease drug onto the World Health Organization's (WHO) list of essential medicines.

22 May 2007

Ranbaxy receives tentative FDA approval for Fexofenadine hydrochloride tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market the antihistamine Fexofenadine Hydrochloride Tablets, 30 mg, 60 mg, and 180 mg.

18 May 2007

Lupin Pharmaceuticals receives FDA approval for Simvastatin tablets

Lupin Pharmaceuticals, Inc. has announced that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Simvastatin Tablets 10mg, 20mg, 40mg and 80mg.

16 May 2007

More power to FDA on drug safety

The Senate overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the market, moving the issue of drug safety to the House, where a strong bill has been introduced but has yet to be considered.

10 May 2007

Review of six large-scale clinical trials of aliskiren

Hypertension is a serious condition affecting millions.Currently there are seven classes of drugs used to reduce blood pressure. Aliskiren (Tekturna , Rasilez) is the first of a new class of orally active antihypertensive drugs that works by inhibiting renin.

10 May 2007

Clinton to the rescue again!

Bill Clinton has done deal with two generic drug companies which will ensure that developing countries will be able to access second line anti-retroviral AIDS drugs at reduced prices.

8 May 2007

Elastic interactions of membrane proteins

Cellular survival relies crucially on the ability to receive and communicate signals from and to the outside world.

4 May 2007

FDA issues "Critical Path Opportunities for Generic Drugs"

The U.S. Food and Drug Administration (FDA) today issued the "Critical Path Opportunities for Generic Drugs" report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

4 May 2007

AIDS Healthcare Foundation praises Thailand for drug stance

AIDS Healthcare Foundation (AHF) has lauded the Government of Thailand for its vow to continue with plans to issue compulsory licenses for the manufacturing and importing of generic versions of lifesaving drugs, including AIDS drugs, despite the fact that the office of United States Trade Representative (USTR), elevated Thailand to its 'Priority Watch' List.

4 May 2007

Senate begins debate on prescription drug user fee act reauthorization bill

The Senate on Monday began debate on a bill (S 1082) that would reauthorize the Prescription Drug User Fee Act, which will expire on Sept. 30, with senators expected to propose a number of amendments to the legislation, the AP/Dallas Morning News reports ( AP/Dallas Morning News , 4/30).

2 May 2007

Generic biologic drugs unlikely to be cheaper than brand-name drugs

Generic versions of a class of medicines called "biologics" would not be significantly cheaper than brand-name versions of the medicines, according to research from professors at Duke University's Fuqua School of Business.

2 May 2007

Web-based disease management program improves outcomes for low-income black students

Low-income African-American high school students with asthma who participated in a specially-designed, web-based disease management program reported fewer days and nights with symptoms, fewer school days missed, fewer days of restricted activity, and less hospitalization for asthma during a 12-month follow-up period, as compared to non-participating asthmatic students.

2 May 2007

PEPFAR 'on track' to meet goals when authorization expires, Dybul says

The President's Emergency Plan for AIDS Relief is "dead on track" to meet its goal of providing antiretroviral drugs to two million people when it's five-year authorization expires in 2008, Ambassador Mark Dybul, who serves as the U.S. global AIDS coordinator and administers PEPFAR, said Thursday in an interview during a visit to San Francisco, the San Francisco Chronicle reports.

1 May 2007

Lawmakers have proposed 'witch's brew' of biotech bills

Lawmakers in recent months "have stirred up a witch's brew of initiatives that is cause for some concern -- not only for the biotech industry, but for all Americans," James Mullen, president and CEO of Biogen and chair of the Biotechnology Industry Organization, writes in a Wall Street Journal opinion piece.

1 May 2007

Brazilian Health Minister says country will purchase generic version of Merck antiretroviral if price not lowered

Brazilian Health Minister Jose Gomes Temporao on Wednesday signed a decree declaring that the country would purchase from an India-based drug maker a generic version of Merck 's antiretroviral Efavirenz if the company does not offer the drug at a lower price, the AP/Forbes reports.

30 Apr 2007

Caraco Pharmaceuticals to market generic Nimotop

Caraco Pharmaceutical Laboratories has announced that it will market Nimodipine Capsules, 30mg (Nimotop) on behalf of Sun Pharmaceutical Industries, Inc. (Sun), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd.

30 Apr 2007

Ranbaxy receives approval to manufacture Pravastatin Sodium tablets in U.S.

Ranbaxy Pharmaceuticals has announced that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Pravastatin Sodium Tablets (Pravastatin), 10 mg, 20 mg, 40 mg and 80 mg, with 180-day market exclusivity in the U.S. healthcare system for the 80 mg strength.

27 Apr 2007

Ranbaxy receives approval to manufacture Zolpidem tablets for insomnia

Ranbaxy Laboratories Limited (RLL), has announced that the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Zolpidem Tartrate Tablets, 5mg and 10mg.

27 Apr 2007